Peter G. Mortimer

5.2k total citations · 1 hit paper
38 papers, 3.6k citations indexed

About

Peter G. Mortimer is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter G. Mortimer has authored 38 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 22 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter G. Mortimer's work include Cancer therapeutics and mechanisms (11 papers), PARP inhibition in cancer therapy (10 papers) and DNA Repair Mechanisms (8 papers). Peter G. Mortimer is often cited by papers focused on Cancer therapeutics and mechanisms (11 papers), PARP inhibition in cancer therapy (10 papers) and DNA Repair Mechanisms (8 papers). Peter G. Mortimer collaborates with scholars based in United Kingdom, South Korea and United States. Peter G. Mortimer's co-authors include Peijun Wu, Andrew Tutt, Mark J. O’Connor, Alan Ashworth, David S. Boss, Stan B. Kaye, James Carmichael, Timothy A. Yap, Marja Mergui‐Roelvink and Jan H.M. Schellens and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Peter G. Mortimer

38 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

2009 2.7k citations Peter C.C. Fong, David S. Boss et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter G. Mortimer United Kingdom	16	2.4k	2.2k	763	655	522	38	3.6k
Shar-yin N. Huang United States	8	1.8k 0.8×	2.3k 1.1×	234 0.3×	174 0.3×	180 0.3×	8	2.9k
Ram Ganapathi United States	33	1.8k 0.7×	2.7k 1.2×	183 0.2×	734 1.1×	705 1.4×	132	4.0k
Małgorzata Z. Zdzienicka Netherlands	36	2.0k 0.8×	4.6k 2.1×	790 1.0×	1.5k 2.3×	266 0.5×	87	5.4k
Anitra Fielding United Kingdom	24	3.7k 1.6×	1.9k 0.9×	1.1k 1.4×	699 1.1×	758 1.5×	57	5.0k
Jill Bargonetti United States	31	3.9k 1.6×	4.2k 1.9×	489 0.6×	1.3k 2.0×	317 0.6×	73	5.8k
Wenbin Zhou China	34	867 0.4×	1.3k 0.6×	204 0.3×	1.2k 1.8×	301 0.6×	108	2.8k
S. Gail Eckhardt United States	36	2.5k 1.1×	2.6k 1.2×	191 0.3×	1.2k 1.8×	1.1k 2.1×	105	5.3k
Patricia Fetsch United States	35	2.1k 0.9×	1.3k 0.6×	219 0.3×	330 0.5×	752 1.4×	73	3.9k
Agnieszka Michael United Kingdom	23	685 0.3×	918 0.4×	497 0.7×	363 0.6×	242 0.5×	85	1.8k
Soo‐Hwang Teo Malaysia	35	1.2k 0.5×	2.2k 1.0×	833 1.1×	918 1.4×	306 0.6×	107	3.6k

Countries citing papers authored by Peter G. Mortimer

Since Specialization

Citations

This map shows the geographic impact of Peter G. Mortimer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter G. Mortimer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter G. Mortimer more than expected).

Fields of papers citing papers by Peter G. Mortimer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter G. Mortimer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter G. Mortimer. The network helps show where Peter G. Mortimer may publish in the future.

Co-authorship network of co-authors of Peter G. Mortimer

This figure shows the co-authorship network connecting the top 25 collaborators of Peter G. Mortimer. A scholar is included among the top collaborators of Peter G. Mortimer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter G. Mortimer. Peter G. Mortimer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Park, Sehhoon, Yu Jung Kim, Young Joo Min, et al.. (2023). Biomarker‐driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer. Cancer. 130(4). 541–552. 15 indexed citations

Suh, Koung Jin, Min‐Hee Ryu, Dae Young Zang, et al.. (2023). AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20). The Oncologist. 28(9). e823–e834. 12 indexed citations

Kim, Seung Tae, Simon A. Smith, Peter G. Mortimer, et al.. (2021). Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. Clinical Cancer Research. 27(17). 4700–4709. 61 indexed citations

Mahdi, Haider, Navid Hafez, Deborah B. Doroshow, et al.. (2021). Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). JCO Precision Oncology. 5(5). 1432–1442. 56 indexed citations

Morscher, Raphael J., Pablo Berlanga, Lynley V. Marshall, et al.. (2021). First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial. European Journal of Cancer. 157. 268–277. 24 indexed citations

Kwon, Minsuk, Minae An, S.T. Kim, et al.. (2021). Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy. Annals of Oncology. 33(2). 193–203. 81 indexed citations

Kim, Jin Won, Ji‐Won Kim, Tae-Yong Kim, et al.. (2021). DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress.. Journal of Clinical Oncology. 39(15_suppl). TPS4166–TPS4166. 4 indexed citations

Lee, Jeeyun, Seung Tae Kim, Simon A. Smith, et al.. (2020). Results from a phase I, open-label study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer (NCT02630199).. Journal of Clinical Oncology. 38(15_suppl). 3503–3503. 11 indexed citations

Kim, Seung Tae, Su Jin Lee, Minhwa Park, et al.. (2019). Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. Translational Oncology. 12(4). 597–601. 10 indexed citations

10.

Bono, Johann S. de, Aaron R. Hansen, Ananya Choudhury, et al.. (2018). AZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Annals of Oncology. 29. viii291–viii292. 8 indexed citations

11.

Hussain, Maha, Paul G. Corn, M. Dror Michaelson, et al.. (2013). Safety, efficacy, and health-related quality of life (HRQoL) of the investigational single agent orteronel (ortl) in nonmetastatic castration-resistant prostate cancer (nmCRPC).. Journal of Clinical Oncology. 31(15_suppl). 5076–5076. 4 indexed citations

12.

George, Daniel J., Paul G. Corn, M. Dror Michaelson, et al.. (2012). Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study.. Journal of Clinical Oncology. 30(15_suppl). 4549–4549. 14 indexed citations

13.

Fong, Peter C.C., David S. Boss, Timothy A. Yap, et al.. (2009). Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. New England Journal of Medicine. 361(2). 123–134. 2698 indexed citations breakdown →

14.

Sabharwal, Ami, Pippa Corrie, Rachel Midgley, et al.. (2009). A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 66(5). 829–835. 13 indexed citations

15.

Watson, Amanda J., Gail McGown, Mary Thorncroft, et al.. (2009). O6-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. British Journal of Cancer. 100(8). 1250–1256. 32 indexed citations

16.

Kefford, Richard, Pippa Corrie, Ehtesham Abdi, et al.. (2009). A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. British Journal of Cancer. 100(8). 1245–1249. 21 indexed citations

17.

Khan, Omar, Michalis Michael, Ian Olver, et al.. (2008). A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. British Journal of Cancer. 98(10). 1614–1618. 45 indexed citations

18.

Mortimer, Peter G., et al.. (1993). The accumulation of five antibacterial agents in porin-deficient mutants of Escherichia coli. Journal of Antimicrobial Chemotherapy. 32(2). 195–213. 85 indexed citations

19.

Mortimer, Peter G. & Laura J. V. Piddock. (1991). A comparison of methods used for measuring the accumulation of quinolones by Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus. Journal of Antimicrobial Chemotherapy. 28(5). 639–653. 159 indexed citations

20.

Mortimer, Peter G., et al.. (1981). Hemiaplasia of the Thyroid with Thyrotoxicosis. The Journal of Clinical Endocrinology & Metabolism. 52(1). 152–155. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact